FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311853065> ?p ?o ?g. }

• W4311853065 endingPage "2743" @default.
• W4311853065 startingPage "2743" @default.
• W4311853065 abstract "Ezetimibe (EZE) is a selective cholesterol absorption inhibitor. Hepatic impairment significantly increases the systemic exposure of EZE and its main active phenolic glucuronide, EZE-Ph. Although changes in efflux transporter activity partly explain the changes in EZE-Ph pharmacokinetics, the causes of the changes to EZE and the effects of the administration route on EZE-Ph remain unclear. A carbon tetrachloride (CCl4)-induced hepatic failure rat model was combined with in vitro experiments to explore altered EZE and EZE-Ph disposition caused by hepatic impairment. The plasma exposure of EZE and EZE-Ph increased by 11.1- and 4.4-fold in CCl4-induced rats following an oral administration of 10 mg/kg EZE, and by 2.1- and 16.4-fold after an intravenous injection. The conversion of EZE to EZE-Ph decreased concentration-dependently in CCl4-induced rat liver S9 fractions, but no change was observed in the intestinal metabolism. EZE-Ph was a substrate for multiple efflux and uptake transporters, unlike EZE. In contrast to efflux transporters, no difference was seen in the hepatic uptake of EZE-Ph between control and CCl4-induced rats. However, bile acids that accumulated due to liver injury inhibited the uptake of EZE-Ph by organic anion transporting polypeptides (OATPs) (glycochenodeoxycholic acid and taurochenodeoxycholic acid had IC50 values of 15.1 and 7.94 μM in OATP1B3-overexpressed cells). In conclusion, the increased plasma exposure of the parent drug EZE during hepatic dysfunction was attributed to decreased hepatic glucuronide conjugation, whereas the increased exposure of the metabolite EZE-Ph was mainly related to transporter activity, particularly the inhibitory effects of bile acids on OATPs after oral administration." @default.
• W4311853065 created "2023-01-01" @default.
• W4311853065 creator A5000564739 @default.
• W4311853065 creator A5001219472 @default.
• W4311853065 creator A5021795655 @default.
• W4311853065 creator A5033020983 @default.
• W4311853065 creator A5060739855 @default.
• W4311853065 creator A5073581902 @default.
• W4311853065 creator A5087491134 @default.
• W4311853065 date "2022-12-08" @default.
• W4311853065 modified "2023-09-29" @default.
• W4311853065 title "Changes in Disposition of Ezetimibe and Its Active Metabolites Induced by Impaired Hepatic Function: The Influence of Enzyme and Transporter Activities" @default.
• W4311853065 cites W1597435471 @default.
• W4311853065 cites W1971901938 @default.
• W4311853065 cites W1989027116 @default.
• W4311853065 cites W1990168972 @default.
• W4311853065 cites W1994302475 @default.
• W4311853065 cites W1995116750 @default.
• W4311853065 cites W2002121467 @default.
• W4311853065 cites W2009059339 @default.
• W4311853065 cites W2022639126 @default.
• W4311853065 cites W2027130771 @default.
• W4311853065 cites W2038457699 @default.
• W4311853065 cites W2048277906 @default.
• W4311853065 cites W2054157154 @default.
• W4311853065 cites W2068222227 @default.
• W4311853065 cites W2069315083 @default.
• W4311853065 cites W2069819211 @default.
• W4311853065 cites W2070897467 @default.
• W4311853065 cites W2072482644 @default.
• W4311853065 cites W2082705528 @default.
• W4311853065 cites W2109972098 @default.
• W4311853065 cites W2113284407 @default.
• W4311853065 cites W2117049083 @default.
• W4311853065 cites W2117592927 @default.
• W4311853065 cites W2122742700 @default.
• W4311853065 cites W2142507996 @default.
• W4311853065 cites W2143855840 @default.
• W4311853065 cites W2152698802 @default.
• W4311853065 cites W2153356268 @default.
• W4311853065 cites W2155690985 @default.
• W4311853065 cites W2159314121 @default.
• W4311853065 cites W2176783202 @default.
• W4311853065 cites W2567340543 @default.
• W4311853065 cites W2751681739 @default.
• W4311853065 cites W2759917944 @default.
• W4311853065 cites W2793943052 @default.
• W4311853065 cites W2887259965 @default.
• W4311853065 cites W2898314774 @default.
• W4311853065 cites W3136593857 @default.
• W4311853065 cites W3165424663 @default.
• W4311853065 cites W3207887499 @default.
• W4311853065 cites W3012080100 @default.
• W4311853065 doi "https://doi.org/10.3390/pharmaceutics14122743" @default.
• W4311853065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36559237" @default.
• W4311853065 hasPublicationYear "2022" @default.
• W4311853065 type Work @default.
• W4311853065 citedByCount "1" @default.
• W4311853065 countsByYear W43118530652023 @default.
• W4311853065 crossrefType "journal-article" @default.
• W4311853065 hasAuthorship W4311853065A5000564739 @default.
• W4311853065 hasAuthorship W4311853065A5001219472 @default.
• W4311853065 hasAuthorship W4311853065A5021795655 @default.
• W4311853065 hasAuthorship W4311853065A5033020983 @default.
• W4311853065 hasAuthorship W4311853065A5060739855 @default.
• W4311853065 hasAuthorship W4311853065A5073581902 @default.
• W4311853065 hasAuthorship W4311853065A5087491134 @default.
• W4311853065 hasBestOaLocation W43118530651 @default.
• W4311853065 hasConcept C104317684 @default.
• W4311853065 hasConcept C112705442 @default.
• W4311853065 hasConcept C149011108 @default.
• W4311853065 hasConcept C149151106 @default.
• W4311853065 hasConcept C181389837 @default.
• W4311853065 hasConcept C185592680 @default.
• W4311853065 hasConcept C200082930 @default.
• W4311853065 hasConcept C202751555 @default.
• W4311853065 hasConcept C2776678969 @default.
• W4311853065 hasConcept C2777477808 @default.
• W4311853065 hasConcept C2777752497 @default.
• W4311853065 hasConcept C2778163477 @default.
• W4311853065 hasConcept C2778657065 @default.
• W4311853065 hasConcept C2779186261 @default.
• W4311853065 hasConcept C2779907587 @default.
• W4311853065 hasConcept C55493867 @default.
• W4311853065 hasConcept C71924100 @default.
• W4311853065 hasConcept C87644729 @default.
• W4311853065 hasConcept C98274493 @default.
• W4311853065 hasConceptScore W4311853065C104317684 @default.
• W4311853065 hasConceptScore W4311853065C112705442 @default.
• W4311853065 hasConceptScore W4311853065C149011108 @default.
• W4311853065 hasConceptScore W4311853065C149151106 @default.
• W4311853065 hasConceptScore W4311853065C181389837 @default.
• W4311853065 hasConceptScore W4311853065C185592680 @default.
• W4311853065 hasConceptScore W4311853065C200082930 @default.
• W4311853065 hasConceptScore W4311853065C202751555 @default.
• W4311853065 hasConceptScore W4311853065C2776678969 @default.
• W4311853065 hasConceptScore W4311853065C2777477808 @default.
• W4311853065 hasConceptScore W4311853065C2777752497 @default.

• next